Prognostic factors and molecular markers for renal cell carcinoma

Matthew H. Bui; Amnon Zisman; Allan J. Pantuck; Ken Ryu Han; Jeff Wieder; Arie S. Belldegrun

doi:10.1586/14737140.1.4.565

Prognostic factors and molecular markers for renal cell carcinoma

Matthew H. Bui, Amnon Zisman, Allan J. Pantuck, Ken Ryu Han, Jeff Wieder, Arie S. Belldegrun^*

^*Corresponding author for this work

University of California at Los Angeles

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer.

Original language	English
Pages (from-to)	565-575
Number of pages	11
Journal	Expert Review of Anticancer Therapy
Volume	1
Issue number	4
DOIs	https://doi.org/10.1586/14737140.1.4.565
State	Published - 2001
Externally published	Yes

Keywords

Classification
Genetics
Kidney
Molecular markets
Prognostic factors
Renal cell
Staging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.1.4.565

Cite this

@article{0659de4dc5ed4eca900480e19c4cf015,

title = "Prognostic factors and molecular markers for renal cell carcinoma",

abstract = "Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer.",

keywords = "Classification, Genetics, Kidney, Molecular markets, Prognostic factors, Renal cell, Staging",

author = "Bui, {Matthew H.} and Amnon Zisman and Pantuck, {Allan J.} and Han, {Ken Ryu} and Jeff Wieder and Belldegrun, {Arie S.}",

year = "2001",

doi = "10.1586/14737140.1.4.565",

language = "אנגלית",

volume = "1",

pages = "565--575",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Prognostic factors and molecular markers for renal cell carcinoma

AU - Bui, Matthew H.

AU - Zisman, Amnon

AU - Pantuck, Allan J.

AU - Han, Ken Ryu

AU - Wieder, Jeff

AU - Belldegrun, Arie S.

PY - 2001

Y1 - 2001

N2 - Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer.

AB - Renal cell carcinoma is the most common cancer in the kidney, affecting nearly 30,000 Americans every year and is associated with over 12,000 deaths annually. If detected early, renal cell carcinomas can be cured surgically. However, once metastatic disease develops the prognosis for long-term survival is poor. Unfortunately, one-third of patients have metastatic disease at the time of diagnosis and approximately 50% of the patients undergoing surgical resection for less advanced disease eventually relapse. This review examines the clinical and molecular prognostic tools currently available or under investigation for kidney cancer.

KW - Classification

KW - Genetics

KW - Kidney

KW - Molecular markets

KW - Prognostic factors

KW - Renal cell

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=0035559915&partnerID=8YFLogxK

U2 - 10.1586/14737140.1.4.565

DO - 10.1586/14737140.1.4.565

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 12113089

AN - SCOPUS:0035559915

SN - 1473-7140

VL - 1

SP - 565

EP - 575

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 4

ER -

Prognostic factors and molecular markers for renal cell carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this